title: Authors' reply to Davies.
authors.affiliation: School of Social and Community Medicine, University of Bristol, Bristol BS8 2PS, UK.
authors.forename: Kyla H
authors.initials: KH
authors.lastname: Thomas
authors.forename: Richard M
authors.initials: RM
authors.lastname: Martin
authors.forename: Neil M
authors.initials: NM
authors.lastname: Davies
authors.forename: Chris
authors.initials: C
authors.lastname: Metcalfe
authors.forename: Frank
authors.initials: F
authors.lastname: Windmeijer
authors.forename: David
authors.initials: D
authors.lastname: Gunnell
mesh_terms: D001552:Benzazepines / Q000009:adverse effects*; D016642:Bupropion / Q000009:adverse effects*; D003863:Depression / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008297:Male; D011810:Quinoxalines / Q000009:adverse effects*; D016728:Self-Injurious Behavior / Q000453:epidemiology*; D012907:Smoking / Q000188:drug therapy*; D016540:Smoking Cessation; D013405:Suicide / Q000706:statistics & numerical data*; D061485:Tobacco Use Cessation Devices / Q000009:adverse effects*
chemical_list: D001552:Benzazepines; D011810:Quinoxalines; D016642:Bupropion